Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) announced on Monday that it has entered into a voluntary agreement with the US Administration to lower prescription drug prices and expand patient access, including across its respiratory portfolio used by more than 40 million Americans with conditions such as asthma and COPD.

The agreement delivers all four actions requested by President Trump in his 31 July letter and includes price reductions for certain medicines in Medicaid, alongside a commitment to launch new products using a more balanced pricing approach that recognises innovation value across developed markets.

GSK plc will also make most of its inhaled respiratory portfolio and selected other medicines available through a direct purchasing platform offering savings of up to 66%, extending its long-standing global commitment to responsible pricing and access.

Under the President's Strategic Active Pharmaceutical Ingredients Reserve, GSK plc will support US supply chain resilience by securing a national reserve of albuterol, the active ingredient used in inhalers for asthma and COPD relief.

These agreements cover both GSK plc and ViiV Healthcare, providing pricing framework clarity and exempting both companies from Section 232 tariffs for three years, with detailed terms remaining confidential.

GSK plc previously announced in September 2025 plans to invest more than USD30bn in US R&D and manufacturing over five years, including USD2bn in new commitments to manufacturing, artificial intelligence and advanced digital technologies, supporting hundreds of skilled jobs and building on its approximately 15,000-strong US workforce.